FDA panel votes to ease access to controversial peptides
An FDA advisory panel voted to recommend that certain compounding pharmacies be allowed to produce at least one of seven controversial peptides, a win for RFK Jr.’s push to broaden peptide access despite FDA safety concerns; final FDA approval remains pending and could be influenced by the panel’s recommendation amid ongoing debates over safety, efficacy, and potential conflicts of interest among advisers.
